The state of Nebraska currently has 7 active clinical trials seeking participants for Healthy research studies. These trials are conducted in various cities, including Omaha, Lincoln, Kearney and Grand Island.
Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants
NCT07039929
Recruiting
This study will be conducted to assess the safety, tolerability, and pharmacokinetics of INCB000631 when administered orally to healthy adult participants.
Gender:
ALL
Ages:
Between 19 years and 55 years
Trial Updated:
08/15/2025
Locations: Celerion, Inc, Lincoln, Nebraska
Conditions: Healthy Participants
Register for Updates
A Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Behavior in the Body of TBD11
NCT06707142
Recruiting
This is a randomized, double-blind, placebo controlled First in human (FIH) trial of TBD11, administered to healthy adults. The trial will be conducted in two parts. Part 1 will consist of single ascending dose (SAD) and Food effect (FE) cohorts, and Part 2 will consist of multiple ascending dose (MAD) cohorts.
Gender:
ALL
Ages:
Between 19 years and 55 years
Trial Updated:
08/01/2025
Locations: Celerion, Lincoln, Nebraska
Conditions: Healthy Adult Participants
Register for Updates
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
NCT06655324
Recruiting
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
07/30/2025
Locations: Velocity Clinical Research Lincoln ( Site 0004), Lincoln, Nebraska +1 locations
Conditions: Healthy
Register for Updates
Integrated Cancer Repository for Cancer Research
NCT02012699
Recruiting
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer... Read More
Gender:
ALL
Ages:
Between 19 years and 110 years
Trial Updated:
06/04/2025
Locations: Mary Lanning Healthcare, Morrison Cancer Center, Hastings, Nebraska +6 locations
Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control, Gastrointestinal Stromal Tumors, Central Nervous System Tumor, Central Nervous System Cancer
Register for Updates
The Short-term Verbal Memory Endophenotype for Developmental Language Disorder Language Disorder
NCT06968169
Recruiting
The goal of this clinical trial is to determine how memory and attention affect the ability of children with developmental language disorder (DLD) to learn and use new vocabulary.
Gender:
ALL
Ages:
Between 5 years and 10 years
Trial Updated:
05/05/2025
Locations: Boys Town National Research Hospital, Omaha, Nebraska
Conditions: Developmental Language Disorder, Healthy Subjects
Register for Updates
First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants
NCT06673667
Recruiting
This is a first-in-human study to evaluate safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-621 in healthy male and female adult participants.
Gender:
ALL
Ages:
Between 19 years and 55 years
Trial Updated:
03/21/2025
Locations: Celerion, Lincoln, Nebraska
Conditions: Healthy Participants Study
Register for Updates
Relative Bioavailability of NX-5948 Tablets Vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets
NCT06717269
Recruiting
This is a 2-cohort, fixed-sequence, 3-period, relative bioavailability, food-effect, and drug-drug interaction study. It is an open-label study evaluating the relative bioavailability of NX-5948 tablets compared to capsules, and the effect of food and an acid-reducing agent on the pharmacokinetics (PK) of NX-5948.
Gender:
ALL
Ages:
Between 19 years and 55 years
Trial Updated:
12/13/2024
Locations: Celerion, Lincoln, Nebraska
Conditions: Healthy Volunteer
Register for Updates